Immune engineers Darrell Irvine and K. Dane Wittrup join Ankyra Therapeutics CEO Howard Kaufman to discuss the evolution of a convergent bench-to-bedside collaboration that uses localized cytokine therapy to awaken a powerful immune response against solid tumors. The company's anchored immunotherapy approach grew directly out of two independent Koch Institute research projects and is expected to begin clinical trials in 2023. Immunologist Stefani Spranger provides an introduction to cancer immunotherapy. The program concludes with a dessert reception in the Koch Institute Public Galleries.